Medifast CEO Daniel Chard Buys $178K in Stock Amidst Activist Agreement
MED is trading near its 52-week low of $9.22 (8.4% above the low).
Summary
Medifast CEO Daniel R. Chard purchased $178,725 worth of company stock on the open market, signaling executive confidence following a recent activist investor agreement and prior financial challenges.
Key Events · Ownership and Investor Activity · MED
-
CEO Open Market Purchase
Daniel R. Chard, Chairman & CEO, purchased 17,678 shares of Medifast common stock for $178,724.58 at an average price of $10.11 per share on March 20, 2026.
-
Routine Tax Withholding
Chard also disposed of 29,808 shares valued at $287,284.45 through mandatory tax withholdings related to restricted stock unit vesting between March 13 and March 25, 2026.
-
Restricted Stock Unit Grants
The CEO received grants of 41,795 restricted stock units on March 25, 2026, which will vest over time as part of his compensation.
-
Strategic Context
This open market purchase follows a cooperation agreement with activist investor Steamboat Capital (March 20, 2026) and comes after the company reported a significant 36% revenue drop and a net loss in its 2025 annual report.
Analysis · MED · Manufacturing
Medifast's CEO, Daniel R. Chard, made an open market purchase of company stock, signaling confidence in the company's future. This purchase, valued at over $178,000, is particularly notable given the company's recent financial performance, which included a significant revenue drop and a net loss reported in its 2025 annual report. The buy also follows closely on the heels of a cooperation agreement with activist investor Steamboat Capital, suggesting a potential alignment or renewed strategic focus. While the CEO also had routine tax-related sales, the open market purchase by a key executive often indicates a belief that the stock is undervalued or that positive developments are ahead.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MED was trading at $9.99 on NYSE in the Manufacturing sector, with a market capitalization of approximately $107.2M. The 52-week trading range was $9.22 to $15.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.